Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Anika to Participate in Upcoming Investor Conferences

Anika Therapeutics,Inc.
Posted on: 25 Aug 16

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced that its Chief Financial Officer, Sylvia Cheung, will participate in the following upcoming investor conferences:

  • Barrington Research Fall Investment Conference on Thursday, September 8, 2016. The conference consists of 1:1 meetings, and it is being held at the Four Seasons hotel in Chicago.
  • Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016. Ms. Cheung is scheduled to present at 5:25 pm ET. The conference is being held at the Grand Hyatt hotel in New York City.
  • Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13, 2016. Ms. Cheung is scheduled to present at 2:35 pm ET. The conference is being held at the Lotte New York Palace hotel in New York City.

Live audio webcasts of the Morgan Stanley and Rodman & Renshaw presentations may be accessed via the “Investor Relations” section of Anika’s website at Audio archives of the presentations also will be available on the website shortly after the conclusion of the conferences.

About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Mass. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing clinically meaningful therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio is comprised of marketed (ORTHOVISC® and MONOVISC®) and pipeline (CINGAL® and HYALOFAST® in the U.S.) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. For more information about Anika, please visit

View source version on

Business Wire

Last updated on: 25/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.